Braves to exercise club option on Chris Sale

The Braves are exercising their club option on left-hander Chris Sale, according to a report from Jon Heyman of The New York Post. Sale will make $18MM in 2026.

The call to pick up Sale’s option for the 2026 campaign is surely one of the easiest option decisions any team will make this offseason. Sale, 36, is one of the best pitchers of his generation and won the NL Cy Young award in 2024. He was on track to compete for the away again this year, with a 2.52 ERA and 2.71 FIP through 15 starts, but he found himself sidelined for ten weeks over the summer due to a ribcage fracture. He looked just as dominant as ever when he returned, however, with a 2.72 ERA and 2.58 FIP across six starts in August and September. His stuff looked just as good as ever down the stretch, and he struck out an eye-popping 36.4% of his opponents in his 36 1/3 innings of work.

That Sale is pitching well is hardly a surprise, as he’s put together a Hall of Fame-caliber resume over the years. A nine-time All-Star who placed in the top five for AL Cy Young award voting six times before winning the NL award last year, Sale’s career 3.01 ERA, 2.88 FIP, and 30.8% strikeout rate know few equals throughout the game. He’s seventh all-time in strikeout rate among starting pitchers, and his run prevention and peripheral numbers match up well with titans of the sport like Clayton Kershaw and Pedro Martinez despite some of his counting numbers being held back by a relative lack of volume.

Fortunately, that relative lack of volume also means a relative lack of mileage on his arm, as compared to other players in his age range. Even with his 37th birthday on the horizon in March, Sale figures to serve as the club’s ace once again in 2026. He’ll be at the front of an Atlanta rotation with a lot of exciting upside but precious little certainty. Spencer Strider has shown the capacity to be a Cy Young caliber arm in the past, but had a disappointing 4.45 ERA in 2025. Spencer Schwellenbach has a career 3.23 ERA but was sidelined after just 17 starts this past season. Reynaldo Lopez had a 1.99 ERA in 2024 but didn’t appear in a game after March 28th this year.

Adding at least one proven, reliable rotation arm to this group figures to be a priority for the Braves this offseason, though it’s possible they could look to do more than that given the group’s collective injury history and questions about Lopez’s ability to handle the workload of a starter long-term. Even with additions likely on the horizon, though, there’s little doubt that Sale will be making his seventh career Opening Day start (and second for the Braves) in 2026 as long as he completes Spring Training with a clean bill of health.